COMP <GO>
SRTS vs ABBV // EV/EBITDA & P/E VALUATION
Sensus Healthcare Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: SRTS 1
— ABBV 10
■ METRIC PARITY
LAST: $2.77 (-1.77%) • MKT CAP: $45.6M
valuation
—
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
valuation
33.3x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SRTS VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SRTS | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 43.20% | 70.20% | -27.00 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -31.30% | 29.00% | -60.30 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | 33.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 0.73% | 3.47% | -2.74 | ABBV | /fcf-yield <GO> |
| Operating Margin | -37.50% | 24.60% | -62.10 | ABBV | /operating-margins <GO> |
| Net Profit Margin | -28.10% | 6.90% | -35.00 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | -34.30% | 8.60% | -42.90 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 6.50 | 5.33 | +1.17 | SRTS | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 7/9 | -2.00 | ABBV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 39.3 | 65.1 | -25.82 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.15 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 113.1x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $45.6M | $513.86B | -$513.81B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SRTS REV | ABBV REV | SRTS GROSS % | ABBV GROSS % | SRTS FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $27.5M | $61.16B | 43.2% | 70.2% | $332.0K | $17.82B |
| FY 2024 | $41.8M | $56.33B | 58.4% | 70.0% | -$1.1M | $17.83B |
| FY 2023 | $24.4M | $54.32B | — | — | -$2.1M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SRTS // BETA —
ABBV // BETA 1.15